Purple Biotech Ltd - ADR Stock
Purple Biotech Ltd - ADR Stock price
Key metrics
| Market capitalization | $9.56m |
| Enterprise Value | $3.54m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| P/B ratio (TTM) P/B ratio | 0.22 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-16.32m |
| Free Cash Flow (TTM) Free Cash Flow | $-17.02m |
| Cash position | $6.30m |
Is Purple Biotech Ltd - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,892 stocks worldwide.
Purple Biotech Ltd - ADR Stock Analysis
Analyst Opinions
2 Analysts have issued a Purple Biotech Ltd - ADR forecast:
Analyst Opinions
2 Analysts have issued a Purple Biotech Ltd - ADR forecast:
Financial data from Purple Biotech Ltd - ADR
| Sep '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | -0.19 -0.19 |
5%
5%
|
|
| EBITDA | -16 -16 |
28%
28%
|
EBIT (Operating Income) EBIT | -16 -16 |
28%
28%
|
| Net Profit | -12 -12 |
45%
45%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Purple Biotech Ltd - ADR directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Purple Biotech Ltd - ADR Stock News
Company Profile
Purple Biotech Ltd. is a development stage pharmaceutical company, which engages in drug development. It operates through two segments: Oncology, and Pain & Hypertension. The Oncology segment includes NT219, a therapeutic candidate which is a small molecule that targets two signal transduction pathways which are involved in the development of cancer drug resistance mechanisms, and which is currently in the late pre-clinical stage of development. The Pain & Hypertension segment includes Consensi, a combination drug for the simultaneous treatment of two clinical conditions, pain caused by osteoarthritis and hypertension (high blood pressure), which can be pre-existing or caused by the treatment for osteoarthritis. The company was founded by John Paul Waymack on August 12, 1968 and is headquartered in Tel Aviv, Israel.
| Head office | Israel |
| CEO | Gil Efron |
| Employees | 20 |
| Founded | 1968 |
| Website | www.purple-biotech.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
